|
NZ618298A
(en)
|
2001-11-13 |
2015-04-24 |
Univ Pennsylvania |
A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
|
|
CN101528916B
(zh)
|
2006-04-28 |
2013-09-04 |
宾夕法尼亚大学托管会 |
规模可调的aav生产方法
|
|
US9725485B2
(en)
|
2012-05-15 |
2017-08-08 |
University Of Florida Research Foundation, Inc. |
AAV vectors with high transduction efficiency and uses thereof for gene therapy
|
|
EP3492596A1
(en)
|
2007-04-09 |
2019-06-05 |
University of Florida Research Foundation, Inc. |
Raav vector compositions having tyrosine-modified capsid proteins and methods for use
|
|
US9217155B2
(en)
|
2008-05-28 |
2015-12-22 |
University Of Massachusetts |
Isolation of novel AAV'S and uses thereof
|
|
US11219696B2
(en)
|
2008-12-19 |
2022-01-11 |
Nationwide Children's Hospital |
Delivery of polynucleotides using recombinant AAV9
|
|
WO2010138263A2
(en)
|
2009-05-28 |
2010-12-02 |
University Of Massachusetts |
Novel aav 's and uses thereof
|
|
WO2011133874A1
(en)
|
2010-04-23 |
2011-10-27 |
University Of Massachusetts |
Multicistronic expression constructs
|
|
EP2561075B1
(en)
|
2010-04-23 |
2018-06-27 |
University of Massachusetts |
Aav-based treatment of cholesterol-related disorders
|
|
US9102949B2
(en)
|
2010-04-23 |
2015-08-11 |
University Of Massachusetts |
CNS targeting AAV vectors and methods of use thereof
|
|
EP3318634A1
(en)
|
2011-04-21 |
2018-05-09 |
University of Massachusetts |
Raav-based compositions and methods for treating diseases involving dominant-negative or gain of function mutations
|
|
US20130039888A1
(en)
|
2011-06-08 |
2013-02-14 |
Nationwide Children's Hospital Inc. |
Products and methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders
|
|
US10815285B2
(en)
*
|
2011-07-01 |
2020-10-27 |
University Of South Florida |
Recombinant adeno-associated virus-mediated expression of fractalkine for treatment of neuroinflammatory and neurodegenerative diseases
|
|
CA2864879C
(en)
|
2012-02-17 |
2021-07-20 |
The Children's Hospital Of Philadelphia |
Aav vector compositions and methods for gene transfer to cells, organs and tissues
|
|
HK1206601A1
(en)
|
2012-04-02 |
2016-01-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of biologics and proteins associated with human disease
|
|
US10501513B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides for the production of oncology-related proteins and peptides
|
|
US9878056B2
(en)
|
2012-04-02 |
2018-01-30 |
Modernatx, Inc. |
Modified polynucleotides for the production of cosmetic proteins and peptides
|
|
US10294281B2
(en)
|
2012-05-15 |
2019-05-21 |
University Of Florida Research Foundation, Incorporated |
High-transduction-efficiency rAAV vectors, compositions, and methods of use
|
|
US12358954B2
(en)
|
2012-05-15 |
2025-07-15 |
University Of Florida Research Foundation, Incorporated |
Capsid-modified rAAV vector compositions and methods therefor
|
|
EP2855684A1
(en)
*
|
2012-05-25 |
2015-04-08 |
Commissariat à l'Énergie Atomique et aux Énergies Alternatives |
Vector for the selective silencing of a gene in astrocytes
|
|
EP3536795A3
(en)
*
|
2012-06-21 |
2019-12-11 |
Association Institut de Myologie |
Widespread gene expression
|
|
PT2879719T
(pt)
*
|
2012-08-01 |
2018-10-08 |
Ohio State Innovation Foundation |
Administração intratecal do vírus adeno-associado 9 recombinante
|
|
US12024568B2
(en)
*
|
2012-09-13 |
2024-07-02 |
Cornell University |
Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodies
|
|
JP2015529685A
(ja)
|
2012-09-17 |
2015-10-08 |
ザ・リサーチ・インスティテュート・アット・ネイションワイド・チルドレンズ・ホスピタルＴｈｅ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ Ａｔｎａｔｉｏｎｗｉｄｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ |
筋萎縮性側索硬化症の処置のための組成物および方法
|
|
HRP20220607T1
(hr)
|
2012-11-26 |
2022-06-24 |
Modernatx, Inc. |
Terminalno modificirana rna
|
|
ES2959747T3
(es)
|
2013-02-15 |
2024-02-28 |
Bioverativ Therapeutics Inc |
Gen del factor VIII optimizado
|
|
AU2014244167A1
(en)
*
|
2013-03-13 |
2015-10-08 |
The Children's Hospital Of Philadelphia |
Adeno-associated virus vectors and methods of use thereof
|
|
CA2905202C
(en)
|
2013-03-14 |
2019-12-31 |
Universite Laval |
Use of electroretinography (erg) for the assessment of psychiatric disorders
|
|
HRP20201063T1
(hr)
|
2013-03-15 |
2020-11-27 |
The Trustees Of The University Of Pennsylvania |
Pripravci za liječenje mpsi
|
|
HK1222093A1
(zh)
*
|
2013-05-15 |
2017-06-23 |
明尼苏达大学董事会 |
腺相关病毒介导的基因向中枢神经系统转移
|
|
IL297919A
(en)
|
2013-07-22 |
2023-01-01 |
Childrens Hospital Philadelphia |
Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues
|
|
DK3024497T3
(da)
*
|
2013-07-26 |
2021-04-12 |
Univ Iowa Res Found |
Fremgangsmåder og præparater til behandling af hjernesygdomme
|
|
PT3039146T
(pt)
|
2013-08-27 |
2020-08-11 |
The Res Institute At Nationwide Childrens Hospital |
Produtos e métodos para tratamento de esclerose lateral amiotrófica
|
|
EP3564379A1
(en)
*
|
2013-09-13 |
2019-11-06 |
California Institute of Technology |
Selective recovery
|
|
CA2927366A1
(en)
*
|
2013-10-24 |
2015-04-30 |
Uniqure Ip B.V. |
Aav-5 pseudotyped vector for gene therapy for neurological diseases
|
|
AU2014346987A1
(en)
|
2013-11-05 |
2016-06-23 |
The Research Institute At Nationwide Children's Hospital |
Compositions and methods for inhibiting NF-kB and SOD-1 to treat amyotrophic lateral sclerosis
|
|
WO2015080223A1
(ja)
*
|
2013-11-29 |
2015-06-04 |
タカラバイオ株式会社 |
アデノ随伴ウイルスの定量方法
|
|
MY184796A
(en)
*
|
2013-12-11 |
2021-04-22 |
Sumitomo Chemical Co |
Method for manufacturing ciliary marginal zone-like structure
|
|
GB201403684D0
(en)
|
2014-03-03 |
2014-04-16 |
King S College London |
Vector
|
|
WO2015127128A2
(en)
*
|
2014-02-19 |
2015-08-27 |
University Of Massachusetts |
Recombinant aavs having useful transcytosis properties
|
|
AU2015231294B2
(en)
*
|
2014-03-18 |
2020-10-29 |
University Of Massachusetts |
rAAV-based compositions and methods for treating amyotrophic lateral sclerosis
|
|
US10975391B2
(en)
|
2014-04-25 |
2021-04-13 |
University Of Massachusetts |
Recombinant AAV vectors useful for reducing immunity against transgene products
|
|
JP6983511B2
(ja)
*
|
2014-04-25 |
2021-12-17 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
脳中の転移乳癌および他の癌を処置するための方法および組成物
|
|
PE20170260A1
(es)
|
2014-05-02 |
2017-04-12 |
Genzyme Corp |
Vectores de aav para la terapia genica de la retina y el snc
|
|
US10689653B2
(en)
|
2014-06-03 |
2020-06-23 |
University Of Massachusetts |
Compositions and methods for modulating dysferlin expression
|
|
WO2015191508A1
(en)
|
2014-06-09 |
2015-12-17 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
|
WO2016004113A1
(en)
|
2014-06-30 |
2016-01-07 |
Biogen Ma Inc. |
Optimized factor ix gene
|
|
WO2016054554A1
(en)
|
2014-10-03 |
2016-04-07 |
University Of Massachusetts |
Heterologous targeting peptide grafted aavs
|
|
WO2016054557A1
(en)
|
2014-10-03 |
2016-04-07 |
University Of Massachusetts |
Novel high efficiency library-identified aav vectors
|
|
CA2964272A1
(en)
|
2014-10-21 |
2016-04-28 |
Guangping Gao |
Recombinant aav variants and uses thereof
|
|
RU2716991C2
(ru)
|
2014-11-05 |
2020-03-17 |
Вояджер Терапьютикс, Инк. |
Полинуклеотиды aadc для лечения болезни паркинсона
|
|
GB201420139D0
(en)
|
2014-11-12 |
2014-12-24 |
Ucl Business Plc |
Factor IX gene therapy
|
|
RU2716422C2
(ru)
|
2014-11-14 |
2020-03-11 |
Вояджер Терапьютикс, Инк. |
Композиции и способы лечения бокового амиотрофического склероза (als)
|
|
CN112410339A
(zh)
|
2014-11-14 |
2021-02-26 |
沃雅戈治疗公司 |
调节性多核苷酸
|
|
KR20240063169A
(ko)
|
2014-11-21 |
2024-05-10 |
더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 |
중추 신경계에 표적화된 aav 벡터
|
|
HK1245326A1
(zh)
|
2014-12-12 |
2018-08-24 |
Voyager Therapeutics, Inc. |
用於生产scaav的组合物和方法
|
|
CA2967468A1
(en)
|
2014-12-16 |
2016-06-23 |
Board Of Regents Of The University Of Nebraska |
Gene therapy for juvenile batten disease
|
|
US20180030096A1
(en)
|
2015-02-03 |
2018-02-01 |
University Of Florida Research Foundation, Inc. |
Recombinant aav1, aav5, and aav6 capsid mutants and uses thereof
|
|
JP2018506304A
(ja)
|
2015-02-10 |
2018-03-08 |
ジェンザイム・コーポレーション |
バリアントＲＮＡｉ
|
|
US10584321B2
(en)
|
2015-02-13 |
2020-03-10 |
University Of Massachusetts |
Compositions and methods for transient delivery of nucleases
|
|
PT3268024T
(pt)
*
|
2015-03-10 |
2020-12-09 |
Univ Columbia |
Construtos de vetor viral recombinante glut1 adeno associado e métodos relacionados para restaurar a expressão de glut1
|
|
CA3021949C
(en)
|
2015-04-24 |
2023-10-17 |
University Of Massachusetts |
Modified aav constructs and uses thereof
|
|
US20170067028A1
(en)
*
|
2015-05-15 |
2017-03-09 |
Douglas J. Ballon |
Radiolabeling of adeno associated virus
|
|
EP3302706A4
(en)
*
|
2015-05-29 |
2019-05-08 |
The Trustees Of The University Of Pennsylvania |
COMPOSITIONS AND METHODS FOR REMOVING MISINTEGRATED PROTEINS
|
|
IL256517B2
(en)
|
2015-06-23 |
2024-06-01 |
Childrens Hospital Philadelphia |
Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues
|
|
WO2017005806A1
(en)
*
|
2015-07-07 |
2017-01-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for expressing a polynucleotide of interest in the peripheral nervous system of a subject
|
|
US10597655B2
(en)
*
|
2015-09-22 |
2020-03-24 |
Loyola University Chicago |
Methods for modulating KLHL1 levels, methods for modulating current activity in T-type calcium channels, molecules therefor, and methods for identifying molecules therefor
|
|
US10047377B2
(en)
*
|
2015-09-22 |
2018-08-14 |
Loyola University Of Chicago |
Methods for modulating KLHL1 levels, methods for modulating current activity in T-type calcium channels, molecules therefor, and methods for identifying molecules therefor
|
|
CN108137655B
(zh)
|
2015-09-28 |
2022-04-22 |
北卡罗来纳-查佩尔山大学 |
逃避抗体的病毒载体的方法和组合物
|
|
WO2017060510A1
(en)
*
|
2015-10-09 |
2017-04-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of alzheimer's disease
|
|
DK3364997T5
(da)
|
2015-10-22 |
2024-09-30 |
Univ Massachusetts |
Aspartoacylase genterapi til behandling af canavans sygdom
|
|
CA3002980A1
(en)
|
2015-10-22 |
2017-04-27 |
University Of Massachusetts |
Prostate-targeting adeno-associated virus serotype vectors
|
|
CN105420275A
(zh)
*
|
2015-11-27 |
2016-03-23 |
中国科学院苏州生物医学工程技术研究所 |
制备外源功能基因定点整合的人神经干细胞的方法
|
|
US10983110B2
(en)
|
2015-12-02 |
2021-04-20 |
Voyager Therapeutics, Inc. |
Assays for the detection of AAV neutralizing antibodies
|
|
US11098286B2
(en)
|
2015-12-11 |
2021-08-24 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for AAV9
|
|
DK3387137T3
(da)
|
2015-12-11 |
2021-05-03 |
California Inst Of Techn |
Målretningspeptider til styring af adeno-associerede virusser (aav`er)
|
|
EP3387117B1
(en)
|
2015-12-11 |
2022-11-23 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aav8
|
|
ES2918998T3
(es)
|
2015-12-11 |
2022-07-21 |
Univ Pennsylvania |
Método de purificación escalable para AAVrh10
|
|
WO2017100674A1
(en)
|
2015-12-11 |
2017-06-15 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aav1
|
|
EP3411478B1
(en)
|
2016-02-01 |
2022-06-08 |
Bioverativ Therapeutics Inc. |
Optimized factor viii genes
|
|
CA3011939A1
(en)
|
2016-02-02 |
2017-08-10 |
University Of Massachusetts |
Method to enhance the efficiency of systemic aav gene delivery to the central nervous system
|
|
MA43968A
(fr)
|
2016-02-03 |
2018-12-12 |
Univ Pennsylvania |
Thérapie génique pour traiter la mucopolysaccharidose de type i
|
|
WO2017139643A1
(en)
*
|
2016-02-12 |
2017-08-17 |
University Of Massachusetts |
Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
|
|
EP3436078B1
(en)
*
|
2016-03-31 |
2021-10-27 |
University of Cincinnati |
Methods and compositions for the treatment of als
|
|
US11207426B2
(en)
|
2016-04-05 |
2021-12-28 |
University Of Massachusetts |
Compositions and methods for selective inhibition of grainyhead-like protein expression
|
|
SG11201808176TA
(en)
|
2016-04-15 |
2018-10-30 |
The Trustees Of The Univ Of Pennsyvania |
Gene therapy for treating mucopolysaccharidosis type ii
|
|
US11413356B2
(en)
|
2016-04-15 |
2022-08-16 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance
|
|
WO2017189959A1
(en)
|
2016-04-29 |
2017-11-02 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
|
WO2017189964A2
(en)
|
2016-04-29 |
2017-11-02 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
|
GB201608046D0
(en)
|
2016-05-09 |
2016-06-22 |
Cambridge Entpr Ltd And Syndey Children S Hospitals Network Randwick And Westmead Incorporating The |
Treatment of complement-mediated disorders
|
|
DK4206216T3
(da)
|
2016-05-13 |
2025-12-01 |
4D Molecular Therapeutics Inc |
Adeno-associerede virusvarianter og fremgangsmåder til brug deraf
|
|
CN109831916B
(zh)
|
2016-05-18 |
2023-07-21 |
沃雅戈治疗公司 |
治疗亨廷顿氏舞蹈病的组合物和方法
|
|
CA3252099A1
(en)
|
2016-05-18 |
2025-06-05 |
Voyager Therapeutics, Inc. |
MODULATING POLYNUCLEOTIDES
|
|
US11882815B2
(en)
|
2016-06-15 |
2024-01-30 |
University Of Massachusetts |
Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
|
|
JP7165357B2
(ja)
*
|
2016-07-26 |
2022-11-04 |
コーネル ユニヴァーシティー |
アルデヒドデヒドロゲナーゼ欠損症の治療のための遺伝子治療
|
|
CA3033856A1
(en)
|
2016-08-15 |
2018-02-22 |
Genzyme Corporation |
Methods for detecting aav
|
|
EP3506817A4
(en)
|
2016-08-30 |
2020-07-22 |
The Regents of The University of California |
Methods for biomedical targeting and delivery and devices and systems for practicing the same
|
|
US10457940B2
(en)
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
|
JP7035033B2
(ja)
|
2016-09-28 |
2022-03-14 |
コーバー、インコーポレイテッド |
治療用ＭＯＴＳ－ｃ関連ペプチド
|
|
DK3525583T3
(da)
|
2016-10-12 |
2025-10-27 |
Bioverativ Usa Inc |
Anti-c1s-antistoffer og fremgangsmåder til anvendelse deraf
|
|
WO2018071831A1
(en)
|
2016-10-13 |
2018-04-19 |
University Of Massachusetts |
Aav capsid designs
|
|
NZ752941A
(en)
|
2016-11-09 |
2023-04-28 |
Intrexon Corp |
Frataxin expression constructs
|
|
US11117930B2
(en)
|
2017-02-23 |
2021-09-14 |
Adrx, Inc. |
Peptide inhibitors of transcription factor aggregation
|
|
MA71412A
(fr)
|
2017-04-03 |
2025-04-30 |
Encoded Therapeutics, Inc. |
Expression de transgène sélective d'un tissu
|
|
MX2019012113A
(es)
|
2017-04-14 |
2020-09-10 |
Univ Nat Taiwan |
Terapia génica para la deficiencia de la aadc.
|
|
JP2020518259A
(ja)
|
2017-05-05 |
2020-06-25 |
ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
ハンチントン病治療組成物および方法
|
|
JP2020518258A
(ja)
|
2017-05-05 |
2020-06-25 |
ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
筋萎縮性側索硬化症（ａｌｓ）治療組成物および方法
|
|
CA3059213A1
(en)
|
2017-05-09 |
2018-11-15 |
University Of Massachusetts |
Methods of treating amyotrophic lateral sclerosis (als)
|
|
WO2018226992A1
(en)
|
2017-06-07 |
2018-12-13 |
Adrx, Inc. |
Tau aggregation inhibitors
|
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
|
BR112020000063A2
(pt)
|
2017-07-06 |
2020-07-14 |
The Trustees Of The University Of Pennsylvania |
terapia gênica mediada por aav9 para tratamento de mucopolissacaridose tipo i
|
|
WO2019018342A1
(en)
|
2017-07-17 |
2019-01-24 |
Voyager Therapeutics, Inc. |
NETWORK EQUIPMENT TRACK GUIDE SYSTEM
|
|
KR102850887B1
(ko)
|
2017-08-03 |
2025-08-28 |
보이저 테라퓨틱스, 인크. |
Aav의 전달을 위한 조성물 및 방법
|
|
NZ763018A
(en)
|
2017-09-20 |
2023-02-24 |
4D Molecular Therapeutics Inc |
Adeno-associated virus variant capsids and methods of use thereof
|
|
CA3076036A1
(en)
|
2017-09-22 |
2019-03-28 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating mucopolysaccharidosis type ii
|
|
WO2019060686A1
(en)
|
2017-09-22 |
2019-03-28 |
University Of Massachusetts |
NEW DUAL EXPRESSION VECTORS OF SOD1 AND USES THEREOF
|
|
EP3684932A1
(en)
|
2017-09-22 |
2020-07-29 |
Genzyme Corporation |
Variant rnai
|
|
MX2020003042A
(es)
*
|
2017-09-29 |
2020-11-18 |
Voyager Therapeutics Inc |
Rescate del fenotipo neurológico central y periférico de la ataxia de friedreich mediante administración intravenosa.
|
|
EP3668997A4
(en)
*
|
2017-10-02 |
2021-05-19 |
Research Institute at Nationwide Children's Hospital |
SYSTEM FOR MIRNA DETARGETING FOR TISSUE-SPECIFIC INTERFERENCE
|
|
CN111465691A
(zh)
|
2017-10-03 |
2020-07-28 |
普利维尔治疗公司 |
用于溶酶体障碍的基因疗法
|
|
KR102709597B1
(ko)
|
2017-10-03 |
2024-09-26 |
프리베일 테라퓨틱스, 인크. |
리소좀 장애를 위한 유전자 요법
|
|
JP7369121B2
(ja)
|
2017-10-11 |
2023-10-25 |
バイオベラティブ・ユーエスエイ・インコーポレイテッド |
補体活性を誘発する方法
|
|
US12441998B2
(en)
*
|
2017-10-12 |
2025-10-14 |
The Trustees Of Columbia University In The City Of New York |
SLC2A1 lncRNA as a biologic and related treatments and methods
|
|
US20200237799A1
(en)
|
2017-10-16 |
2020-07-30 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis (als)
|
|
CN119242711A
(zh)
|
2017-10-16 |
2025-01-03 |
沃雅戈治疗公司 |
肌萎缩性侧索硬化症（als）的治疗
|
|
PT3717636T
(pt)
|
2017-11-27 |
2023-05-30 |
4D Molecular Therapeutics Inc |
Cápsides variantes de vírus adeno-associado e utilização para inibir a angiogénese
|
|
AU2018375163A1
(en)
|
2017-11-30 |
2020-06-11 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for mucopolysaccharidosis IIIB
|
|
JP7389744B2
(ja)
|
2017-11-30 |
2023-11-30 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
ムコ多糖症ｉｉｉａ型のための遺伝子療法
|
|
JP7401432B2
(ja)
|
2017-12-01 |
2023-12-19 |
エンコーデッド セラピューティクス， インコーポレイテッド |
操作されたｄｎａ結合タンパク質
|
|
CN112368051A
(zh)
*
|
2018-03-23 |
2021-02-12 |
马萨诸塞大学 |
用于治疗骨病的基因治疗剂
|
|
JP7406677B2
(ja)
|
2018-04-03 |
2023-12-28 |
ギンコ バイオワークス インコーポレイテッド |
抗体を回避するウイルスベクター
|
|
SG11202009451VA
(en)
|
2018-04-03 |
2020-10-29 |
Stridebio Inc |
Antibody-evading virus vectors
|
|
CA3094465A1
(en)
|
2018-04-03 |
2019-10-10 |
Stridebio, Inc. |
Virus vectors for targeting ophthalmic tissues
|
|
WO2019200016A1
(en)
|
2018-04-10 |
2019-10-17 |
President And Fellows Of Harvard College |
Aav vectors encoding clarin-1 or gjb2 and uses thereof
|
|
JP7575273B2
(ja)
|
2018-04-16 |
2024-10-29 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
デュシェンヌ型筋ジストロフィーを治療するための組成物及び方法
|
|
WO2019210137A1
(en)
|
2018-04-27 |
2019-10-31 |
Voyager Therapeutics, Inc. |
Methods for measuring the potency of aadc viral vectors
|
|
WO2019222329A1
(en)
|
2018-05-15 |
2019-11-21 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
BR112020023082A2
(pt)
|
2018-05-15 |
2021-02-09 |
Voyager Therapeutics, Inc. |
composições e métodos para o tratamento de doença de parkinson
|
|
US12163129B2
(en)
|
2018-06-08 |
2024-12-10 |
University Of Massachusetts |
Antisense oligonucleotides to restore dysferlin protein expression in dysferlinopathy patient cells
|
|
WO2019241486A1
(en)
|
2018-06-13 |
2019-12-19 |
Voyager Therapeutics, Inc. |
Engineered 5' untranslated regions (5' utr) for aav production
|
|
US12297241B2
(en)
|
2018-07-06 |
2025-05-13 |
The Regents Of The University Of California |
Method to engineer transplantable human tissues
|
|
CN112703198B
(zh)
*
|
2018-07-11 |
2025-05-30 |
布里格姆妇女医院 |
用于跨血脑屏障递送试剂的方法和组合物
|
|
WO2020023612A1
(en)
|
2018-07-24 |
2020-01-30 |
Voyager Therapeutics, Inc. |
Systems and methods for producing gene therapy formulations
|
|
BR112021001878A2
(pt)
*
|
2018-07-31 |
2021-04-27 |
Cornell University |
métodos de terapia genética para o controle da função do órgão
|
|
EP3830107A2
(en)
|
2018-08-03 |
2021-06-09 |
Voyager Therapeutics, Inc. |
Aav variants with enhanced tropism
|
|
WO2020028816A1
(en)
|
2018-08-03 |
2020-02-06 |
Genzyme Corporation |
Variant rnai against alpha-synuclein
|
|
US20210177989A1
(en)
*
|
2018-08-30 |
2021-06-17 |
Rowan University |
Methods of Treating or Preventing Amyotrophic Lateral Sclerosis
|
|
CN113966399A
(zh)
|
2018-09-26 |
2022-01-21 |
加州理工学院 |
用于靶向基因疗法的腺相关病毒组合物
|
|
CA3114621A1
(en)
|
2018-09-28 |
2020-04-02 |
Voyager Therapeutics, Inc. |
Frataxin expression constructs having engineered promoters and methods of use thereof
|
|
US12467046B2
(en)
|
2018-10-02 |
2025-11-11 |
Voyager Therapeutics, Inc. |
Redirection of tropism of AAV capsids
|
|
WO2020072849A1
(en)
|
2018-10-04 |
2020-04-09 |
Voyager Therapeutics, Inc. |
Methods for measuring the titer and potency of viral vector particles
|
|
CA3115248A1
(en)
|
2018-10-05 |
2020-04-09 |
Voyager Therapeutics, Inc. |
Engineered nucleic acid constructs encoding aav production proteins
|
|
US20210371470A1
(en)
|
2018-10-12 |
2021-12-02 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
CA3116701A1
(en)
|
2018-10-15 |
2020-04-23 |
Voyager Therapeutics, Inc. |
Expression vectors for large-scale production of raav in the baculovirus/sf9 system
|
|
WO2020117898A1
(en)
*
|
2018-12-05 |
2020-06-11 |
Abeona Therapeutics Inc. |
Recombinant adeno-associated viral vector for gene delivery
|
|
EP3908326A4
(en)
*
|
2018-12-21 |
2022-10-26 |
The Trustees of The University of Pennsylvania |
COMPOSITIONS FOR THE SPECIFIC DRG REDUCTION OF TRANSGEN EXPRESSION
|
|
AU2020216135A1
(en)
|
2019-01-28 |
2021-08-05 |
Cohbar, Inc. |
Therapeutic peptides
|
|
WO2020174369A2
(en)
|
2019-02-25 |
2020-09-03 |
Novartis Ag |
Compositions and methods to treat bietti crystalline dystrophy
|
|
US20220154210A1
(en)
|
2019-02-25 |
2022-05-19 |
Novartis Ag |
Compositions and methods to treat bietti crystalline dystrophy
|
|
CA3132369A1
(en)
|
2019-03-04 |
2020-09-10 |
Duke University |
Compositions and methods for the diagnosis and treatment of retinopathies
|
|
CA3133453A1
(en)
|
2019-03-21 |
2020-09-24 |
Daniel Mccoy |
Recombinant adeno-associated virus vectors
|
|
EP3966231A4
(en)
*
|
2019-04-10 |
2022-12-21 |
University of Massachusetts |
Factor h vectors and uses thereof
|
|
CN114026115A
(zh)
|
2019-04-10 |
2022-02-08 |
普利维尔治疗公司 |
用于溶酶体病症的基因疗法
|
|
WO2020210592A1
(en)
*
|
2019-04-12 |
2020-10-15 |
University Of Massachusetts |
Recombinant aav gene therapy for ngyl1 deficiency
|
|
BR112021021502A2
(pt)
*
|
2019-04-29 |
2022-07-19 |
Univ Pennsylvania |
Capsídeos de aav e composições contendo os mesmos
|
|
US20220243225A1
(en)
|
2019-04-29 |
2022-08-04 |
Voyager Therapeutics, Inc. |
SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS
|
|
WO2020223280A1
(en)
|
2019-04-29 |
2020-11-05 |
Voyager Therapeutics, Inc. |
Aav variants with enhanced tropism
|
|
WO2020227515A1
(en)
|
2019-05-07 |
2020-11-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
|
|
US20220226501A1
(en)
*
|
2019-05-31 |
2022-07-21 |
Universitat Autònoma De Barcelona |
Insulin gene therapy
|
|
EP3983077A4
(en)
*
|
2019-06-17 |
2023-12-20 |
Alnylam Pharmaceuticals, Inc. |
DELIVERY OF OLIGONUCLEOTIDES TO THE STRIATUM
|
|
US11446084B2
(en)
|
2019-07-12 |
2022-09-20 |
Neuralink Corp. |
Laser drilling of pia mater
|
|
US20220281922A1
(en)
|
2019-08-02 |
2022-09-08 |
Voyager Therapeutics, Inc. |
Aav variants with enhanced tropism
|
|
US20220290182A1
(en)
|
2019-08-09 |
2022-09-15 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
|
GB2587319A
(en)
*
|
2019-08-12 |
2021-03-31 |
Healing Genes Llc |
Genetic construct
|
|
TW202122582A
(zh)
|
2019-08-26 |
2021-06-16 |
美商航海家醫療公司 |
病毒蛋白之控制表現
|
|
EP4022073A4
(en)
*
|
2019-08-29 |
2023-12-20 |
The Board Of Trustees Of The Leland Stanford Junior University |
ADENO-ASSOCIATED VIRAL VECTORS TO CROSS THE HUMAN BLOOD-BRAIN BARRIER
|
|
US20220333133A1
(en)
|
2019-09-03 |
2022-10-20 |
Voyager Therapeutics, Inc. |
Vectorized editing of nucleic acids to correct overt mutations
|
|
US12403164B2
(en)
|
2019-09-30 |
2025-09-02 |
Bioverativ Therapeutics Inc. |
Lentiviral vector formulations
|
|
TW202128736A
(zh)
*
|
2019-10-17 |
2021-08-01 |
美商史崔德生物公司 |
用於治療ｃ型尼曼—匹克病之腺相關病毒載體
|
|
US20220106609A1
(en)
*
|
2019-12-17 |
2022-04-07 |
Nikegen, Llc |
Paravoviral vectors and methods of making and use thereof
|
|
CA3167290A1
(en)
*
|
2020-01-10 |
2021-07-15 |
The Brigham And Women's Hospital, Inc. |
Methods and compositions for delivery of immunotherapy agents across the blood-brain barrier to treat brain cancer
|
|
US20210261625A1
(en)
|
2020-01-29 |
2021-08-26 |
Genzyme Corporation |
Modified adeno-associated viral capsid proteins for ocular gene therapy and methods of use thereof
|
|
US12442017B2
(en)
|
2020-03-02 |
2025-10-14 |
National University Corporation Gunma University |
Microglial selective gene expression vector
|
|
EP4128270A4
(en)
|
2020-03-26 |
2024-04-03 |
Diamentis Inc. |
SYSTEMS AND METHODS FOR PROCESSING RETINAL SIGNAL DATA AND IDENTIFYING CONDITIONS
|
|
IL297200A
(en)
|
2020-04-15 |
2022-12-01 |
Voyager Therapeutics Inc |
tau binding compounds
|
|
GB202005732D0
(en)
*
|
2020-04-20 |
2020-06-03 |
Synpromics Ltd |
Regulatory nucleic acid sequences
|
|
CN115461066A
(zh)
*
|
2020-04-28 |
2022-12-09 |
美国辉瑞有限公司 |
用于基因疗法的编码天冬氨酸酰化酶(aspa)的经修饰的核酸和载体
|
|
KR20230010670A
(ko)
|
2020-05-12 |
2023-01-19 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
이식유전자 발현의 drg-특이적 감소를 위한 조성물
|
|
CN116096734A
(zh)
|
2020-05-13 |
2023-05-09 |
沃雅戈治疗公司 |
Aav衣壳的向性的重定向
|
|
WO2021247995A2
(en)
|
2020-06-04 |
2021-12-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating neuropathic pain
|
|
JP2023537565A
(ja)
|
2020-06-24 |
2023-09-04 |
バイオベラティブ セラピューティクス インコーポレイテッド |
タンパク質を発現するように改変されたレンチウイルスベクターの調製物から遊離第ｖｉｉｉ因子を除去する方法
|
|
GB202010981D0
(en)
|
2020-07-16 |
2020-09-02 |
Ucl Business Ltd |
Gene therapy for neuromuscular and neuromotor disorders
|
|
KR20230044522A
(ko)
*
|
2020-08-05 |
2023-04-04 |
항저우 엑제제네시스 바이오 엘티디. |
척수성 근위축을 치료하기 위한 핵산 구축물 및 이의 용도
|
|
US20230295656A1
(en)
|
2020-08-06 |
2023-09-21 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
|
CN116745409A
(zh)
|
2020-08-19 |
2023-09-12 |
萨雷普塔治疗公司 |
用于治疗雷特综合征的腺相关病毒载体
|
|
US12129287B2
(en)
|
2020-09-14 |
2024-10-29 |
President And Fellows Of Harvard College |
Recombinant adeno associated virus encoding clarin-1 and uses thereof
|
|
CN116783298A
(zh)
*
|
2020-11-04 |
2023-09-19 |
贝林格尔.英格海姆国际有限公司 |
供治疗ild、pf-ild和ipf之用的病毒载体和核酸
|
|
US20240050593A1
(en)
*
|
2020-12-18 |
2024-02-15 |
Duke University |
Compositions For and Methods of Enhancing Spinal Cord Tissue Regeneration
|
|
TW202246516A
(zh)
|
2021-03-03 |
2022-12-01 |
美商航海家醫療公司 |
病毒蛋白之控制表現
|
|
WO2022187548A1
(en)
|
2021-03-03 |
2022-09-09 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
WO2022192708A1
(en)
*
|
2021-03-11 |
2022-09-15 |
Temple University- Of The Commonwealth System Of Higher Education |
Noninvasive aav vectors for highly efficient gene delivery to the nervous system
|
|
CN117157309A
(zh)
|
2021-05-28 |
2023-12-01 |
上海瑞宏迪医药有限公司 |
衣壳变异的重组腺相关病毒及其应用
|
|
US20250001008A1
(en)
*
|
2021-07-01 |
2025-01-02 |
Bridgebio Gene Therapy Research, Inc. |
Gene therapy for galactosemia
|
|
WO2023044483A2
(en)
|
2021-09-20 |
2023-03-23 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
CA3235145A1
(en)
|
2021-10-12 |
2023-04-20 |
Bridgebio Gene Therapy Llc |
Methods and compositions for treating leukodystrophies
|
|
US20250001012A1
(en)
|
2021-11-02 |
2025-01-02 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
US20250295807A1
(en)
|
2021-11-15 |
2025-09-25 |
The Trustees Of The University Of Pennsylvania |
Compositions for drg-specific reduction of transgene expression
|
|
US20250051750A1
(en)
|
2021-11-29 |
2025-02-13 |
Shanghai Regenelead Therapies Co., Ltd. |
Aadc/gdnf polynucleotide, and use thereof in treating parkinson's disease
|
|
EP4469585A2
(en)
|
2022-01-25 |
2024-12-04 |
Voyager Therapeutics, Inc. |
Baculovirus expression system
|
|
AU2023220237A1
(en)
|
2022-02-21 |
2024-08-15 |
Shanghai Regenelead Therapies Co., Ltd |
Vegf-binding molecule and pharmaceutical use thereof
|
|
CN119343458A
(zh)
|
2022-04-12 |
2025-01-21 |
建新公司 |
Irak4调节剂用于基因疗法的用途
|
|
US20230407255A1
(en)
|
2022-04-12 |
2023-12-21 |
Genzyme Corporation |
Dendritic cell assay for innate immunogenicity to gene therapy agents
|
|
IL316231A
(en)
|
2022-04-12 |
2024-12-01 |
Genzyme Corp |
Using IRAK4 modulators for gene therapy
|
|
CA3250230A1
(en)
*
|
2022-04-22 |
2023-10-26 |
The General Hospital Corporation |
SPECIFIC PROMOTER OF THE HUMAN EPENDYMA AND ITS USES
|
|
US20250295809A1
(en)
|
2022-05-13 |
2025-09-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
WO2023240236A1
(en)
|
2022-06-10 |
2023-12-14 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of spinal muscular atrophy related disorders
|
|
WO2023250388A1
(en)
|
2022-06-22 |
2023-12-28 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
|
WO2024027632A1
(en)
*
|
2022-08-01 |
2024-02-08 |
Skyline Therapeutics (Shanghai) Co., Ltd. |
Novel plasmid backbone to reduce dna impurities in raav preparation
|
|
WO2024054983A1
(en)
|
2022-09-08 |
2024-03-14 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
CN120019071A
(zh)
|
2022-09-15 |
2025-05-16 |
沃雅戈治疗公司 |
Tau结合化合物
|
|
GB2622629A
(en)
|
2022-09-23 |
2024-03-27 |
Sania Rx Ltd |
Method
|
|
US20250197862A1
(en)
|
2023-12-15 |
2025-06-19 |
Genzyme Corporation |
ARTIFICIAL microRNAs TARGETING TAU
|
|
WO2025158385A1
(en)
|
2024-01-25 |
2025-07-31 |
Genzyme Corporation |
Pegylated il-2 for suppressing adaptive immune response to gene therapy
|
|
WO2025160434A1
(en)
|
2024-01-26 |
2025-07-31 |
Genzyme Corporation |
Artificial micrornas targeting huntington's disease
|
|
WO2025160429A1
(en)
|
2024-01-26 |
2025-07-31 |
Genzyme Corporation |
Artificial micrornas targeting snca
|
|
GB202406331D0
(en)
|
2024-05-07 |
2024-06-19 |
Sania Rx Ltd |
Capsid
|
|
WO2025235643A1
(en)
|
2024-05-08 |
2025-11-13 |
Genzyme Corporation |
Profiling of gene therapy agents
|